The focus on disease-modifying therapies (DMTs) has shifted from managing symptoms to altering the disease progression and targeting the mechanisms underlying AD, such as Aβ plaques, acetylcholinesterase, and tau tangle accumulation. This evidence concerns the gene MAPT and Alzheimer disease.